BioCentury
ARTICLE | Company News

Eli Lilly, Yabao Pharmaceutical Group deal

October 26, 2015 7:00 AM UTC

The companies partnered to co-develop Lilly’s sodium-glucose cotransporter 1 (SGLT1) inhibitor to treat diabetes. Yabao received Chinese rights to develop and commercialize the compound, while Lilly ...